Keeping Track Of Breakthroughs: AZ Farxiga, ImmunoGen ADC For Hematologic Cancer, Inventiva NASH Candidate Earn Designation

 
• By Bridget Silverman

The latest breakthrough therapy designation news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Person running; breakthrough concept
The DAPA-CKD study on Farxiga’s was stopped early in March 2020 because of “overwhelming efficacy.” • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards